Nav: Home

Biologic treatments for inflammatory bowel disease help heal the intestine

March 22, 2017

Although anti-inflammatory treatments are quite effective at reducing symptoms in patients with Crohn's disease and ulcerative colitis, the mucosal lining of the intestine often remains ulcerated, and many patients still ultimately require surgery. Because of this, the goal of treatment is shifting towards mucosal healing rather than just symptom relief.

A recent analysis of clinical trials shows that anti-tumour necrosis factor a (anti-TNF) agents such as infliximab and adalimumab are much more effective than placebo at maintaining mucosal healing in Crohn's disease (28% versus 1%). In ulcerative colitis, the anti-TNFs and anti-integrins were equally more effective than placebo (33% versus 18%). These are encouraging results, but there is still a long way to go to achieve 100% healing.

"As we are entering the era where we anticipate there will be many new treatments, each targeting inflammation differently, it is also important to understand the relative efficacy of these therapies in achieving our goal of mucosal healing to appropriately position them in our treatment algorithms," said Dr. Ashwin Ananthakrishnan, senior author of the Alimentary Pharmacology & Therapeutics review.
-end-


Wiley

Related Ulcerative Colitis Articles:

Fecal microbiota transplant is safe and effective for patients with ulcerative colitis
A single transplant of microbes contained in the stool of a healthy donor is a safe and effective way to increase diversity of good bacteria in the guts of patients with ulcerative colitis, according to new research from Weill Cornell Medicine and NewYork-Presbyterian.
Yoga helps patients with ulcerative colitis
Patients with ulcerative colitis, a chronic inflammatory bowel disease, often relapse at times of stress.
Crohn's & Colitis Foundation and AGA announce conference partnership
The Crohn's & Colitis Foundation and the American Gastroenterological Association announced today that they are partnering to co-sponsor the first-ever 'Crohn's & Colitis Congress,' which will take place in Las Vegas in January 2018.
Low level vitamin D during remission contributes to relapse in ulcerative colitis patients
A new study led by researchers at Beth Israel Deaconess Medical Center (BIDMC) has found that lower levels of vitamin D in the blood increase the risk of clinical relapse in patients with Ulcerative Colitis (UC), an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the colon.
U-M researchers discover what makes drug for ulcerative colitis tick
For approximately 70 years, physicians have used a medication containing the active agent mesalamine to treat ulcerative colitis, but little was known about how the drug targeted the inflammatory bowel disease.
Protozoan parasite increases risk of colitis, study reveals
Researchers from the University of Toronto have discovered that mice infected with the common gut parasite Tritrichomonas muris are at an increased risk of developing inflammatory colitis.
Iron-deficiency anemia in ulcerative colitis -- many patients don't get testing and treatment
Many patients with ulcerative colitis don't receive recommended testing and treatment for the common problem of iron deficiency anemia, reports a study in the October issue of Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA).
Transplanting healthy stool might be an answer to ulcerative colitis
Fecal microbiota transplantation -- a treatment currently used to address recurring Clostridium difficile infection -- is also an effective approach to helping individuals who suffer from ulcerative colitis, according to a study being presented at Digestive Disease Week®.
Study advances understanding of colon cancer and colitis
The transcription factor hepatocyte nuclear factor 4-alpha (HNF4-alpha) plays a key role in colon cancer and colitis.
Study shows ozanimod as effective in treating ulcerative colitis
Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis.

Related Ulcerative Colitis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".